Malignant Glioma — Trials

Malignant Glioma — Trials · CancerIndex

Clinical trials

Registered studies

2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 589
Recruiting: 314
Ph III recruiting: 16
Growth YoY: +38.9%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (324)

clinicaltrialsPublishedShowing 301–350 of 850 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05664243	A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma	active not recruiting	Phase 1 / Phase 2	4	In8bio Inc.INDUSTRY	1	May 1, 2025	clinicaltrials
NCT06936046	Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression	recruiting	Phase 2	200	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER